查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2151496

抗肥胖藥物市場規模、佔有率和趨勢分析報告：按產品、作用機制、分銷管道、地區和細分市場預測（2026-2033 年）

Anti-obesity Medication Market Size, Share & Trends Analysis Report By Product, By Mechanism Of Action, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

全球抗肥胖藥物市場預計到 2025 年價值 195 億美元，到 2026 年將成長到 257 億美元，到 2033 年擴大到 1,764 億美元，2026 年至 2033 年的複合年成長率為 31.7%。

北美是市場的主要驅動力，預計到2025年將佔全球銷售額的37.0%。人們對超重健康影響的日益關注正在推動市場成長。此外，高效能GLP-1受體促效劑和新一代減重療法的日益普及也顯著加速了市場擴張。

在大量研發投入的支持下，抗肥胖藥物研發的加速發展預計將推動市場成長。隨著藥物研發技術的進步，市場預計將進一步成長，以滿足應對與超重相關的健康挑戰的迫切需求。 2025年3月，世界肥胖聯盟發布了《世界肥胖地圖集》，預測2010年至2030年間，全球肥胖成年人數將成長超過115%，從5.24億增加到約11.3億。報告指出，三分之二的國家缺乏大多數重要的國家級肥胖控制政策，只有7%的國家擁有能夠有效應對肥胖問題的醫療保健系統。

此外，超重或肥胖每年導致約160萬人過早死亡，死因包括糖尿病、癌症、心臟病和中風等疾病。日益嚴重的肥胖問題和醫療基礎設施不足預計將加速對藥物治療的需求，從而推動市場擴張。此外，肥胖盛行率的預期成長與市場成長直接相關，為製藥公司、醫療服務提供者和其他相關人員創造了商機。隨著與肥胖相關的醫療保健成本持續上升，亟需創新解決方案和乾預措施來遏制這一流行病，並確保醫療保健成本的永續控制。

市場參與者正積極投資研發，以開發用於體重管理的創新藥物。例如，2025年10月，禮來公司公佈了一項III期臨床試驗的積極初步結果，該試驗表明，口服GLP-1受體促效劑orfoglipron能夠顯著減輕肥胖或超重成年人的體重，並改善其心血管代謝風險因素。預計這些進展將加劇市場競爭，拓寬治療選擇，並加速市場成長。

CagriSema、Oral Sema Obesity、GELA、INV-202 和 Olfolglipron 等新藥的上市正在推動市場成長。投資該領域能夠幫助企業抓住不斷變化的需求所帶來的機遇，並獲得競爭優勢。透過引領創新藥物的研發和商業化，企業可以確立自身作為產業先驅的地位，並鞏固其市場地位。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：抗肥胖藥物市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 抗肥胖藥物市場分析工具

第4章：抗肥胖藥物市場：產品具體估算與趨勢分析

  • 全球抗肥胖藥物市場：依產品分類，展望
  • 全球抗肥胖藥物市場：基於產品的規模和趨勢分析，2021-2033年
  • 已通過核准的
    • 仿單標示外用藥

第5章：抗肥胖藥物市場：依作用機制進行估算與趨勢分析

  • 全球抗肥胖藥物市場趨勢分析
  • 2021-2033年全球抗肥胖藥物市場規模及作用機轉趨勢分析
  • 周邊作用藥物
  • 中樞作用藥物

第6章：抗肥胖藥物市場：按分銷管道分類的估算與趨勢分析

  • 全球抗肥胖藥物市場趨勢分析
  • 全球抗肥胖藥物市場：按分銷管道分類的市場規模和趨勢分析（2021-2033年）
  • 零售藥房
  • 醫院藥房
  • 其他

第7章：抗肥胖藥物市場：區域估算與趨勢分析

  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司和競爭對手的分類
  • 供應商情況
    • 主要銷售代理商和通路夥伴名單
    • Key customers
    • Key company market share analysis, 2023
    • Novo Nordisk A/S
    • GSK plc
    • Novartis AG
    • VIVUS LLC
    • Currax Pharmaceuticals LLC
    • Boehringer Ingelheim International GmbH
    • Rhythm Pharmaceuticals, Inc.
    • Gelesis
Product Code: GVR-4-68040-235-6

The global anti-obesity medication market size was valued at USD 19.5 billion in 2025 and is projected to grow from USD 25.7 billion in 2026 to USD 176.4 billion by 2033, growing at a CAGR of 31.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 37.0% in 2025. Increasing awareness of the health consequences of being overweight fuels market growth. In addition, the rising adoption of highly effective GLP-1 receptor agonists and next-generation weight loss therapies is significantly accelerating market expansion.

Accelerated development of anti-obesity drugs, supported by significant R&D investments, is expected to drive market growth. With advancements in drug development technologies, the market is poised for further growth, addressing the pressing need to combat overweight-related health challenges. In March 2025, the World Obesity Federation published the World Obesity Atlas, which projects that the number of obese adults will grow by more than 115% from 2010 to 2030, rising from 524 million to around 1.13 billion. The report states that two-thirds of countries lack most key national obesity policies, and only 7% have health systems adequately prepared to address obesity.

Furthermore, overweight and obesity are associated with approximately 1.6 million premature deaths annually from conditions including diabetes, cancer, heart disease, and stroke. The growing burden of obesity and inadequate healthcare preparedness is expected to accelerate demand for pharmacological interventions, thereby supporting market expansion. Moreover, the projected increase in obesity prevalence directly correlates with market growth, creating opportunities for pharmaceutical companies, healthcare providers, and other stakeholders. As healthcare costs associated with obesity continue to escalate, there is a growing imperative for innovative solutions and interventions to curb this epidemic and ensure sustainable healthcare cost containment.

Market players are actively investing in R&D to develop innovative medicines for weight management. For instance, in October 2025, Eli Lilly reported successful topline results from the Phase III trial, in which oral GLP-1 receptor agonist orforglipron achieved significant weight reduction and improvements in cardiometabolic risk factors in adults with obesity or overweight. These advancements are expected to intensify competition, broaden therapeutic options, and accelerate market growth.

The introduction of new medications such as CagriSema, Oral Sema Obesity, GELA, INV-202, and orforglipron is propelling the market growth. Investing in this sector enables companies to seize opportunities arising from evolving demands and gain a competitive edge. Leading the development and commercialization of innovative medications positions companies as frontrunners, consolidating their market presence.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Mechanism of Action
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Mechanism of Action outlook
    • 2.2.3. Distribution Channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anti-Obesity Medication Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Prevalence of Obesity-Related Conditions
      • 3.2.1.2. Government Regulations and Guidelines
      • 3.2.1.3. Increase in technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Side Effects and Adverse Reactions
      • 3.2.2.2. High cost of anti-obesity drugs
  • 3.3. Anti-Obesity Medication Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Anti-Obesity Medication Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Anti-Obesity Medication Market by Product Outlook
  • 4.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Approved
    • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.1. Bupropion-naltrexone (Contrave)
        • 4.4.1.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.2. Liraglutide (Saxenda)
        • 4.4.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.3. Orlistat
        • 4.4.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.1.3.2. Xenical
          • 4.4.1.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.1.3.3. Alli
          • 4.4.1.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.4. Phentermine-topiramate (Qsymia)
        • 4.4.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.5. Semaglutide (Wegovy)
        • 4.4.1.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.6. Setmelanotide (Imcivree)
        • 4.4.1.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.7. Tirzepatide (Zepbound)
        • 4.4.1.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Off Label
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.1.1. Semaglutide (Ozempic)
          • 4.4.2.1.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.1.2. Liraglutide (Victoza)
          • 4.4.2.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.1.3. Dulaglutide (Trulicity)
          • 4.4.2.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.1.4. Topiramate (Dulaglutide (Trulicity))
          • 4.4.2.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.1.5. Other
          • 4.4.2.1.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Anti-Obesity Medication Market: Mechanism of Action Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Anti-Obesity Medication Market Movement Analysis
  • 5.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Mechanism of Action, 2021 to 2033 (USD Million)
  • 5.4. Peripherally Acting Drugs
    • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. Centrally Acting Drugs
    • 5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Anti-Obesity Medication Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Anti-Obesity Medication Market Movement Analysis
  • 6.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Hospital Pharmacies
    • 6.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Anti-Obesity Medication Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Novo Nordisk A/S
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. GSK plc
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Novartis AG
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. VIVUS LLC
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Currax Pharmaceuticals LLC
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Boehringer Ingelheim International GmbH
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Rhythm Pharmaceuticals, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Gelesis
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives

List of Tables

  • Table 1 List of key distributors and channel partners
  • Table 2 List of key emerging companies'/technology disruptors/innovators
  • Table 3 North America Anti-Obesity Medication Market, by country, 2021 - 2033 (USD Million)
  • Table 4 North America Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 5 North America Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 6 North America Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 7 U.S. Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 8 U.S. Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 9 U.S. Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 10 Canada Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 11 Canada Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 12 Canada Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 13 Europe Anti-Obesity Medication Market, by country, 2021 - 2033 (USD Million)
  • Table 14 Europe Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 15 Europe Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 16 Europe Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 17 Germany Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 18 Germany Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 19 Germany Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 20 UK Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 21 UK Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 22 UK Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 23 France Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 24 France Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 25 France Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 26 Italy Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 27 Italy Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 28 Italy Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 29 Spain Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 30 Spain Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 31 Spain Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 32 Denmark Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 33 Denmark Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 34 Denmark Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 35 Sweden Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 36 Sweden Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 37 Sweden Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 38 Norway Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 39 Norway Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 40 Norway Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 41 Asia Pacific Anti-Obesity Medication Market, by country, 2021 - 2033 (USD Million)
  • Table 42 Asia Pacific Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 45 Japan Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 46 Japan Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 47 Japan Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 48 China Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 49 China Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 50 China Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 51 India Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 52 India Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 53 India Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 54 Australia Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 55 Australia Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 56 Australia Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 57 South Korea Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 58 South Korea Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 59 South Korea Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 60 Thailand Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 61 Thailand Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 62 Thailand Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 63 Latin America Anti-Obesity Medication Market, by country, 2021 - 2033 (USD Million)
  • Table 64 Latin America Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 65 Latin America Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 66 Latin America Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 67 Brazil Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 68 Brazil Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 69 Brazil Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 70 Mexico Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 71 Mexico Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 72 Mexico Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 73 Argentina Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 74 Argentina Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 75 Argentina Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 76 MEA Anti-Obesity Medication Market, by country, 2021 - 2033 (USD Million)
  • Table 77 MEA Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 78 MEA Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 79 MEA Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 80 South Africa Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 81 South Africa Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 82 South Africa Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 85 Saudi Arabia Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 86 UAE Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 87 UAE Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 88 UAE Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 89 Kuwait Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 90 Kuwait Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 91 Kuwait Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Anti-Obesity Medication Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain - based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Anti-Obesity Medication Market snapshot (2023)
  • Fig. 9 Anti-Obesity Medication Market: Segment snapshot (2023)
  • Fig. 10 Competitive Insights (2023)
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Anti-Obesity Medication Market driver impact
  • Fig. 15 Anti-Obesity Medication Market restraint impact
  • Fig. 16 Clinical chemistry industry challenges
  • Fig. 17 Porter's Five Forces Analysis
  • Fig. 18 SWOT Analysis, By Factor (Political & legal Economic and technological)
  • Fig. 19 Strategic alliance analysis
  • Fig. 20 Recent developments & impact analysis, by key market participants
  • Fig. 21 Key company market share analysis, 2023
  • Fig. 22 Company market position analysis
  • Fig. 23 Definition and scope, by product
  • Fig. 24 Product market share analysis, 2023 & 2030
  • Fig. 25 Segment dashboard
  • Fig. 26 Global Anti-Obesity Medication Market, by product, 2021 - 2033 (USD Million)
  • Fig. 27 Approved market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 28 Bupropion - naltrexone (Contrave) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 29 Liraglutide (Orlistat) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 30 Orlistat market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 31 Xenical market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 32 Alli market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 33 Phentermine - topiramate (Qsymia) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 34 Semaglutide (Wegovy) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 35 Tirzepatide (Zepbound) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 36 Setmelanotide (Imcivree) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 37 Off Label market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 38 Semaglutide (Ozempic) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 39 Liraglutide (Victoza) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 40 Dulaglutide (Trulicity) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 41 Topiramate (Dulaglutide (Trulicity)) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 42 Others market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 43 Definition and scope, by Distribution Channel
  • Fig. 44 Distribution Channel market share analysis, 2023 & 2030
  • Fig. 45 Segment dashboard
  • Fig. 46 Global Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Fig. 47 Retail Pharmacies market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 48 Hospital Pharmacies market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 49 Others market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 50 North America market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 51 U.S. market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 52 Canada market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 53 Europe market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 54 UK market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 55 Germany market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 56 Spain market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 57 France market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 58 Italy market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 59 Sweden market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 60 Denmark market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 61 Norway market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 62 Asia Pacific market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 63 China market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 64 Japan market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 65 India market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 66 Australia market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 67 South Korea market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 68 Thailand market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 69 Latin America market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 70 Brazil market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 71 Mexico market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 72 Argentina market size, & forecasts and trend analysis, 2021 to 2033 (USD Million))
  • Fig. 73 Middle East and Africa market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 74 South Africa market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 75 Saudi Arabia market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 76 UAE market size, & forecasts and trend analysis, 2021 to 2033(USD Million)
  • Fig. 77 Kuwait market size, & forecasts and trend analysis, 2021 to 2033(USD Million)